NCT03220399View on ClinicalTrials.gov

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2019

Primary Completion Date

March 28, 2020

Study Completion Date

July 31, 2020

Conditions
Healthy
Interventions
DRUG

NVP-1603-1 (P)

1capsule, single oral dosing

DRUG

NVP-1603-2 (T)

1tablet, single oral dosing

DRUG

NVP-1603-1 and NVP-1603-2 (P+T)

1capsule and 1tablet co-administration, oral single dosing

Sponsors

Lead Sponsor

NVP Healthcare
All Listed Sponsors
lead

NVP Healthcare

INDUSTRY

NCT03220399 - Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 | Biotech Hunter | Biotech Hunter